Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback